<mods:mods xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" version="3.3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mods="http://www.loc.gov/mods/v3"><mods:titleInfo><mods:title>ENDOTHELIN-1 IN PATIENTS WITH ISCHEMIC HEART DISEASE</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">G`opirjonova D.D</mods:namePart><mods:namePart type="family">G`opirjonova D.D</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Alyavi A.L</mods:namePart><mods:namePart type="family">Alyavi A.L</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Ishemia or ischemic heart disease is the leading cause of disability and premature deaths worldwide. IHD is a condition in which the heartis starved of oxygen due to a redused blood spply. Deapite a large pool of interesting candidate biomarkers, endothelin-1 (ET-1) appears to be involvedin multiple aspecis of IHD pathogenesis that include neurohormonal activation, cardiac remodeling, endothelial dysfunction, inflammation, atherosclerosis and alteration of the renal function. ET-1 production and release can be upregulated by inflammatory factors, such as IFN-γ and IL-1β, during disease</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2024-05-15</mods:dateIssued></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>